This stepwise approach minimizes gastrointestinal side effects but means that full appetite-suppressing effects may not manifest until patients reach higher doses, often at 1.7 mg or 2.4 mg weekly for weight management indications
Ozempic was FDA-approved for type 2 diabetes in 2017, and Wegovy (a higher dose of semaglutide approved for weight loss) in 2021
There may be a labeling error, or there may be a contamination issue
Chronic vomiting is one of the main signs of gastroparesis, and some people who filed lawsuits experienced persistent vomiting after taking Ozempic
Competing Interests Professor Melanie Davies has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for Abbvie, Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Sanofi, Zealand Pharma Regeneron, GSK and EktaH and as a speaker for AstraZeneca and Boehringer Ingelheim